Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.84
+0.310020.26%
Post-market: 1.79-0.0500-2.72%19:52 EDT
Volume:282.18K
Turnover:480.26K
Market Cap:11.14M
PE:-0.08
High:1.84
Open:1.56
Low:1.55
Close:1.53
Loading ...

BioXcel Therapeutics Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) to Continue Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
27 May

BioXcel granted extension to regain compliance with Nasdaq listing requirement

TIPRANKS
·
27 May

BioXcel Therapeutics Granted Extension to Regain Compliance With Nasdaq Continued Listing Requirement

THOMSON REUTERS
·
27 May

BioXcel Therapeutics Inc expected to post a loss of $6.66 a share - Earnings Preview

Reuters
·
05 May

BRIEF-Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through Canaccord - SEC Filing

Reuters
·
04 Apr

BioXcel Therapeutics Inc: May Offer and Sell Shares of Common Stock of up to $8.1 Mln From Time to Time Through Canaccord - SEC Filing

THOMSON REUTERS
·
04 Apr

Bank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
28 Mar

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

BioXcel Therapeutics Q4 2024 GAAP EPS $(3.57) Beats $(6.59) Estimate, Sales $366K Miss $706.667K Estimate

Benzinga
·
27 Mar

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -3.57 Vs. IBES Estimate USD -6.22

Reuters
·
27 Mar

BioXcel Therapeutics Q4 Revenue USD 366 Thousand VS. Ibes Estimate USD 706.7 Thousand

THOMSON REUTERS
·
27 Mar

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

GlobeNewswire
·
27 Mar

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Zacks
·
20 Mar

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
19 Mar

BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
19 Mar

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week

Insider Monkey
·
10 Mar

BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial

Dow Jones
·
08 Mar

BioXcel Therapeutics Inc expected to post a loss of $6.38 a share - Earnings Preview

Reuters
·
07 Mar

BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial

TIPRANKS
·
07 Mar

BRIEF-Bioxcel Therapeutics Announces 33% Enrollment In Serenity At-Home Pivotal Phase 3 Safety Trial

Reuters
·
07 Mar